Country: United States
Language: English
Source: NLM (National Library of Medicine)
METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E)
Sandoz Inc.
METRONIDAZOLE
METRONIDAZOLE 10 mg in 1 g
TOPICAL
PRESCRIPTION DRUG
Metronidazole gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. Metronidazole gel USP, 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. Risk Summary Available data have not established an association with metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. No fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. The available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of metronidazole gel USP, 1%. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Risk Summary It is not known whether metronidazole is present in human milk after topical administration. Published literature reports the presence of metronidazole in human milk after oral administration. There are reports of diarrhea and candida infection in breastfed infants of mothers receiving oral treatment with metronidazole. There are no data on the effects of metronidazole on milk production. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with metronidazole gel USP, 1%. Safety and effectiveness in pediatric patients have not been established. Sixty-six subjects aged 65 years and older were treated with metronidazole gel USP, 1% in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Metronidazole Gel USP, 1% is clear, colorless to pale yellow in color, and supplied as follows: 60 gram tube – NDC 0781-7080-35 55 gram pump – NDC 0781-7080-55 Storage Conditions: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
METRONIDAZOLE- METRONIDAZOLE GEL SANDOZ INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE METRONIDAZOLE GEL USP, 1% SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR METRONIDAZOLE GEL USP, 1%. METRONIDAZOLE GEL USP, 1% FOR TOPICAL USE. INITIAL U.S. APPROVAL: 1963 INDICATIONS AND USAGE Metronidazole gel USP, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. (1) DOSAGE AND ADMINISTRATION ● Not for oral, ophthalmic, or intravaginal use. (2) ● Cleanse treated areas before the application of metronidazole gel USP, 1%. (2) ● Apply and rub in a thin film of metronidazole gel USP, 1% once daily to affected area(s). (2) ● Cosmetics may be applied after the application of metronidazole gel USP, 1%. (2) DOSAGE FORMS AND STRENGTHS Gel, 1%. (3) CONTRAINDICATIONS Metronidazole gel USP, 1% is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. (4) WARNINGS AND PRECAUTIONS Neurologic Disease: Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. The appearance of abnormal neurologic signs should prompt immediate reevaluation of metronidazole gel USP, 1% therapy. (5.1) Blood Dyscrasias: Metronidazole gel USP, 1% is a nitroimidazole and should be used with care in patients with evidence of, or history of, blood dyscrasia. (5.2) Contact Dermatitis: If dermatitis occurs, patients may need to discontinue use. (5.3) Eye Irritation: Topical metronidazole has been reported to cause tearing of the eyes. Therefore, avoid contact with the eyes. (5.4) ADVERSE REACTIONS Most common adverse reactions (incidence > 2%) are nasopharyngitis, upper respiratory tract infection, and headache. TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SANDOZ INC. AT 1 Read the complete document